Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Bloomberg Customers

Seattle Genetics Rises on Positive Trial Data: Seattle Mover

Seattle Genetics Inc., maker of the Hodgkin lymphoma drug Adcetris, is trading at its highest level in more than two months after reporting positive data from additional studies on the medicine.

The drugmaker gained 6 percent to $19.61 at the close in New York, its biggest single-day increase since Nov. 30 and its highest price since Nov. 3. Shares have jumped 15 percent in the past 12 months.

Adcetris was approved in August for patients with Hodgkin lymphoma for whom other therapies have failed, the first new medicine cleared by U.S. regulators for the disease since 1977. The drug had a 65 percent response rate according to interim results of a Phase 2 clinical trial of patients with cutaneous T-cell lymphoma, the company said yesterday at a medical meeting in San Francisco. Three stages of clinical trials are usually required for U.S. regulatory approval.

The potential for Adcetris in indications outside its approved use is being underestimated, Jason Kantor, an analyst with RBC Capital Markets in San Francisco, wrote in a note to clients. “This and other future data releases should begin to spur off-label use” of the drug.

Adcetris, known chemically as brentuximab, is Seattle Genetics’s first product. Sales of the medicine may surpass $275 million in 2014, according to the average estimate of three analysts surveyed by Bloomberg.

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.